GlassScriptPhysician profile
Kaylee S Friedman
NPI 1295400711
$1,251.45
in general payments reported to CMS, 2019-2025
21 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.67 · 2022: $693 · 2023: $232 · 2024: $125 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $303.76 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $168.75 | 2022-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $145.24 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $128.49 | 2022-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $67.92 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $66.74 | 2022-2023 | |
| Exact Sciences Corporation | $46.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $44.98 | 2022 | |
| Tanabe Pharma America, INC. | $42.10 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.23 | 2021-2023 | Relistor |
| Neurelis, INC. | $29.82 | 2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.78 | 2025 | |
| Eisai INC. | $20.31 | 2021 | |
| Glaxosmithkline, LLC. | $18.26 | 2023 | Trelegy Ellipta |
| Alnylam Pharmaceuticals INC. | $16.62 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $16.43 | 2022 | |
| Valinor Pharma, LLC | $14.41 | 2023 | Movantik |
| Mylan Specialty L.P. | $13.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2022 | |
| Amgen INC. | $13.08 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylee Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.